<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105087</url>
  </required_header>
  <id_info>
    <org_study_id>21F.624</org_study_id>
    <nct_id>NCT05105087</nct_id>
  </id_info>
  <brief_title>Contrast-Enhanced Ultrasound Imaging Scan for the Detection of Sentinel Lymph Nodes in Patients With Cervical, Vaginal, or Vulvar Cancer</brief_title>
  <official_title>Detection of Sentinel Lymph Nodes in Female Lower Genital Tract Cancer Patients With Contrast-Enhanced Ultrasound Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares the use of ultrasound for the detection of sentinel lymph nodes&#xD;
      (SLNs) to the standard of care (which varies depending on cancer treatment). The ultrasound&#xD;
      contrast agent is called Sonazoid and it consists of tiny gas-filled bubbles about the side&#xD;
      of red blood cells. Diagnostic procedures, such as ultrasound with Sonazoid, may help&#xD;
      identify more SLNs than standard of care in patients with cervical, vaginal, or vulvar&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the concordance between lymphosonography and the standard of care in the&#xD;
      identification sentinel lymph nodes (SLNs) in patients with cervical, vaginal or vulvar&#xD;
      cancer.&#xD;
&#xD;
      II. To determine if lymphosonography can identify more SLNs with metastatic deposits in&#xD;
      patients with cervical, vaginal or vulvar cancer when compared to the standard of care.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive perflubutane microbubble (Sonazoid) injections subdermally and then undergo&#xD;
      ultrasound over 30 minutes before standard of care cancer treatment.&#xD;
&#xD;
      After completion of study intervention, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of sentinel lymph nodes (SLNs) identified by lymphosonography as well as blue dye or positron emission tomography (PET)-computed tomography (CT)</measure>
    <time_frame>At end of treatment; approximately 30 minutes</time_frame>
    <description>The number of SLN detected by contrast enhanced ultrasound will be compared to the number of SLN detected by the standard of care (i.e., by blue dye or by PET-CT) using paired t-test or paired Wilcoxon test (depending on whether the data is normal distributed or not).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cervical Carcinoma</condition>
  <condition>Malignant Female Reproductive System Neoplasm</condition>
  <condition>Vaginal Carcinoma</condition>
  <condition>Vulvar Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (perflubutane microbubble, ultrasound)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perflubutane Microbubble</intervention_name>
    <description>Given subdermally</description>
    <arm_group_label>Diagnostic (perflubutane microbubble, ultrasound)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast-Enhanced Ultrasound</intervention_name>
    <description>Undergo ultrasound</description>
    <arm_group_label>Diagnostic (perflubutane microbubble, ultrasound)</arm_group_label>
    <other_name>CEUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be female&#xD;
&#xD;
          -  Be diagnosed with cervical, vaginal or vulvar cancer&#xD;
&#xD;
          -  Be at least 18 years of age&#xD;
&#xD;
          -  If of child-bearing potential, must have a negative pregnancy test&#xD;
&#xD;
          -  Be able to comply with study procedures&#xD;
&#xD;
          -  Have read and signed the Institutional Review Board (IRB)-approved informed consent&#xD;
             form for participating in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant or nursing&#xD;
&#xD;
          -  Patients who have received an investigational drug in the 30 days before study drug&#xD;
             administration, or will receive one within 72 hours afterwards&#xD;
&#xD;
          -  Patients who are medically unstable, patients who are seriously or terminally ill, and&#xD;
             patients whose clinical course is unpredictable. For example:&#xD;
&#xD;
               -  Patients on life support or in a critical care unit&#xD;
&#xD;
               -  Patients with clinically unstable cardiac arrhythmias, such as recurrent&#xD;
                  ventricular tachycardia&#xD;
&#xD;
               -  Patients with recent cerebral hemorrhage&#xD;
&#xD;
               -  Patients who have undergone surgery within 24 hours prior to the study&#xD;
                  sonographic examination&#xD;
&#xD;
          -  Patients with congenital heart defects&#xD;
&#xD;
          -  Patient with a known allergy to Sonazoid (including an anaphylactic allergy to eggs or&#xD;
             egg products)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Flemming Forsberg, PhD</last_name>
      <phone>215-955-4870</phone>
      <email>Flemming.Forsberg@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

